MMNope, you certainly can't, the numbers are too small for...

MM

Nope, you certainly can't, the numbers are too small for anything except an indication.  To flip it round, how will you feel heading into P2 if the responses are mediocre - excellent immune response, but nothing to suggest real benefit over SOC?  Statements from IMU have been quite bullish for the last year or so and with that comes expectations.  They've also appointed some highly qualified people to the SAB, are cracking on with the P2 and are pushing hard with PD-1.  All of this raises expectations and the end point is - how did the patients do?

Correct, no two patients are the same, but this bunch all have HER2 in common and presumably the inclusion criteria have selected a relatively similar bunch.  Besides, they've chosen gastric cancer for this trial, but isn't it really a test of how well Her-vaxx can target HER2 cancer?  Surely the LT aim is to have it available for any HER2 cancer that might benefit in which case there will be huge variation between patients.  Their OSU trial info shows an endpoint of Proof of Concept and has a mix of cancers with HER2 in common. 

Cheers